See also ETF lists for: Equity, Global sectors, Health care

Strongest Trends Summary For Motif Global sectors, Health care

Global sectors, Health care ETF is in the long-term up 27% in 4 years.

 

See how to gain 20% in 14 sec with TrendsInvesting

 

You can switch the trend horizon using links provided in the summary above.

Share on StockTwits

Upward trend on Globalsectors Healthcare - up 27.39% in 3 years

Equity, Global sectors, Health care ETFs
IRY

[IRY] SPDR S&P International HealthCareSe

The investment seeks investment results that, before fees and expenses, correspond generally to the total return performance of an index that tracks the health care sector of developed global markets outside the United States. The fund employs a sampling strategy in seeking to track the performance of the S&P Developed Ex-U.S. BMI Health Care Sector Index. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index or in American Depositary Receipts ("ADRs") or Global Depositary Receipts ("GDRs") based on securities comprising the index.

IXJ

[IXJ] iShares S&P Global Healthcare Sect.

The investment seeks to track the investment results of an index composed of global equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the S&P Global 1200 Health Care Sector IndexTM, which measures the performance of companies that S&P Dow Jones Indices LLC ("S&P"), a subsidiary of McGraw Hill Financial, Inc., deems to be a part of the healthcare sector of the economy and that S&P believes are important to global markets. The fund is non-diversified.

Strongest Trends Summary Related To Global sectors, Health care

Global sectors, Health care ETF is in the long-term up 27% in 4 years.

 

News

2019-06-12 08:28:15

Traders Look to Buy Global Health Care Stocks

2018-08-09 12:45:43

Investors Flocked to Healthcare ETFs in July

2018-08-02 10:47:18

5 Strong Healthcare ETFs to Buy

2018-05-09 10:31:32

Merck’s Immunology and Cardiovascular Products in 1Q18

2018-04-13 09:35:02

Why Soft March Payrolls Aren’t a Weak Sign for the Economy

2018-04-04 10:33:33

Johnson & Johnson’s Quarterly Revenue Trend in 2017

2018-04-02 07:30:56

How Eli Lilly’s Cardiovascular Products Performed in 4Q17

2018-04-02 07:30:14

Analysts’ Recommendations for Bristol-Myers Squibb in March 2018

2018-03-29 16:30:00

BlackRock Announces Share Split for Four iShares ETFs

2018-03-15 16:50:02

Pfizer’s Segment-by-Segment Performance in 4Q17

2018-03-07 10:31:34

Johnson & Johnson’s Consumer Segment in 4Q17

2018-01-31 10:05:21

President Trump’s State of the Union Speech Is Market Positive

2018-01-30 15:50:12

Eli Lilly’s 4Q17 Estimates: Revenue Growth Expected

2018-01-25 09:38:21

Analysts’ Estimates for Pfizer’s 4Q17 Earnings

2018-01-18 17:30:03

Merck & Co.’s Business Segments and Performance in 3Q17

2018-01-09 10:48:52

7 Best Healthcare ETFs for 2018

2017-10-02 13:27:36

9 Million American Children Lost Funding For Their Insurance

2017-09-12 09:06:23

Assessing Merck’s Immunology and Cardiovascular Franchise in 2Q17

2017-09-11 08:36:46

What’s Gilead Sciences’ Valuation?

2017-09-05 09:07:28

Performance of AstraZeneca’s CVMD Segment in 2Q17

2017-09-01 07:37:06

Novartis on the Street: Analysts’ Recommendations after 2Q17

2017-08-29 15:05:43

Bristol-Myers Squibb’s Revenues in 2Q17

2017-08-23 09:07:28

Inside Incyte’s Jakafi Performance in 2Q17

2017-07-26 15:09:26

AstraZeneca’s 2Q17 Earnings: Analysts’ Estimates

2017-07-25 07:37:01

Major Developments for Johnson and Johnson

2017-07-18 10:37:48

Analyst Ratings and Recommendations for Novartis Post 2Q17

2017-07-17 10:37:52

Inside Allergan’s International Business

2017-07-11 07:37:36

How Celgene Stock Performed in 2Q17

2017-07-05 07:37:21

Johnson & Johnson’s Medical Devices Business in 1Q17

2017-07-04 10:36:21

Performance of Merck’s Diabetes Drugs in 1Q17

2017-06-28 09:06:20

Pfizer’s Geographical Performance in 1Q17

2017-06-22 07:36:18

Changes in Bristol-Myers Squibb’s Profitability 1Q17

2017-06-05 10:36:28

Performance of Elanco in 1Q17

2017-05-31 07:36:58

Exploring the Performance of AstraZeneca’s CVMD Segment in 1Q17

2017-05-30 17:05:53

Johnson & Johnson’s Business Segments in 1Q17

2017-05-29 14:05:43

AstraZeneca’s Segment-by-Segment Performance in 1Q17

2017-05-25 09:06:33

Performance of Merck’s Animal Health Segment in 1Q17

2017-05-08 11:26:30

Allergan’s 1Q17 Earnings: Analysts’ Estimates

2017-05-05 17:36:10

Pfizer’s Geographical Performance in 1Q17

2017-05-01 10:39:07

How Did GlaxoSmithKline’s HIV Business Perform in 1Q17?

2017-05-01 07:37:08

Novartis’s Valuation after 1Q17 Earnings

2017-04-27 15:36:08

Novartis’s 1Q17 Earnings: Segment Performances

2017-04-26 10:36:53

Analyst Ratings and Recommendations for GlaxoSmithKline

2017-04-26 09:07:19

GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare

2017-04-25 16:28:42

What Analysts Expect of Bristol-Myers Squibb’s 1Q17 Earnings

2017-04-25 07:40:14

GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates

2017-04-24 07:38:09

Novartis’s 1Q17 Estimates for Sandoz

2017-04-13 15:05:47

Johnson & Johnson’s Revenue Estimates: Expect Growth!

2017-04-10 09:06:29

Examining Gilead Sciences’ 1Q17 Performance

2017-04-07 13:35:57

Assessing Johnson & Johnson’s 1Q17 Performance

2017-04-05 07:36:02

Must-Know Corporate and Pipeline Developments for Pfizer

2017-04-03 07:36:16

How Eli Lilly’s New Products Performed in 2016

2017-03-30 10:36:33

What Wall Street Analysts Estimate for GlaxoSmithKline

2017-03-29 10:36:23

Performance of GlaxoSmithKline’s HIV Business in 2016

2017-03-14 07:36:56

Johnson & Johnson’s Pharmaceuticals Segment

2017-03-02 07:37:13

How Gilead’s Other Products Fared in 2016

2017-02-28 09:07:31

Strong Performance of AstraZeneca’s Brilinta and Farxiga in 2016

2017-02-24 16:53:02

Pfizer’s Valuation after Its 4Q16 Earnings Release

2017-02-24 09:07:51

Eli Lilly & Co.’s Endocrine Franchise

2017-02-14 15:05:43

Performance of GlaxoSmithKline’s Pharmaceuticals Segment in 4Q16

2017-02-03 09:06:16

Why the Majority of Analysts Deem Novartis a ‘Buy’

2017-01-31 09:08:59

Analyzing Merck & Co.’s Revenue Estimates in 4Q16

2017-01-31 07:37:56

Opdivo: Bristol-Myers Squibb’s Blockbuster Oncology Drug

2017-01-31 07:35:57

Johnson & Johnson’s Valuation Cheat Sheet

2017-01-30 09:06:06

Exploring JNJ’s 2017 Profitability and Financial Guidance

2017-01-26 15:05:48

Johnson & Johnson’s 4Q16 Performance by Business Segment

2017-01-26 07:37:11

How Will Eli Lilly’s Neuroscience Franchise Fare in 4Q16?

2017-01-24 10:38:19

How Bristol-Myers Squibb’s Oncology Drug Performed in 4Q16

2017-01-23 10:37:05

Novartis’s 4Q16 Estimates: How Could Sandoz Perform?

2017-01-20 07:38:49

Why Johnson & Johnson’s 4Q16 Revenues Could Grow

2017-01-12 11:49:00

The 'Trump Rally' in Stocks Is Ending -- Here's How You Can Profit

2016-12-30 10:36:44

A Look at GlaxoSmithKline’s HIV Business

2016-12-30 07:38:05

Exploring GlaxoSmithKline’s Business Segments

2016-12-29 17:05:32

GlaxoSmithKline’s Revenue Trend

2016-12-29 15:27:42

How GlaxoSmithKline’s Valuation Compares to Its Peers’

2016-12-09 08:06:42

How Does Johnson & Johnson’s Valuation Compare to Its Peers?

2016-12-01 08:05:57

Inside Merck’s Business Segment-Wise Performance

2016-11-29 13:26:47

Allergan’s Valuation Compared to Its Peers

2016-11-23 11:04:33

Inside Eli Lilly’s Neuroscience Franchise

2016-10-28 18:02:41

What Can We Expect of Pfizer’s 3Q16 Earnings?

2016-10-24 10:05:06

Novartis’s 3Q16 Estimates: How Has Sandoz Performed?

2016-10-24 10:04:47

Word on the Street about Merck’s Animal Health Segment

2016-10-21 11:04:52

How Did Johnson & Johnson’s Pharmaceutical Segment Do in 3Q16?

2016-10-19 11:05:32

Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise

2016-10-14 14:04:05

Johnson & Johnson’s Pharmaceuticals Segment: 3Q16 Estimates

2016-09-19 11:04:30

AstraZeneca Is Taking Steps to Improve Its Position in Oncology

2016-09-16 10:04:57

Roche Sees Soaring Revenue from Its Bladder Cancer Treatment

2016-09-16 08:04:56

Roche’s Oncology Wheelhouse Stacked with Competitive Drugs

2016-09-09 18:04:29

What Investors Can Glean from GlaxoSmithKline’s Revenue Trend

2016-09-09 16:04:58

GlaxoSmithKline’s Fundamentals Show It Has Lots of Room to Run

2016-08-30 12:19:06

Is Johnson & Johnson’s Valuation High Compared to Its Peers?

2016-08-27 00:01:00

[$$] Why Investors Should Think Global

2016-08-25 11:04:05

AstraZeneca’s Recent Product Developments

2016-08-25 08:04:05

AstraZeneca and Its Oncology Segment’s Growth in 2Q16

2016-08-24 08:04:05

How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16

2016-08-16 11:04:54

Remicade Is Driving Down Merck’s Immunology Franchise

2016-08-04 11:04:13

How Are Eli Lilly’s New Products Performing?

2016-08-03 09:04:30

Revenues from Eli Lilly’s Cymbalta Are Depressed Internationally

2016-08-01 10:32:59

What to Expect from Pfizer’s 2Q16 Earnings

2016-07-22 13:14:29

How Did JNJ’s Pharmaceutical Segment Fare in 2Q16?

2016-07-22 13:07:45

Understanding Lilly’s New Product Expectations for 2Q16

2016-07-22 13:07:35

Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise

2016-07-06 09:05:29

Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma

2016-05-14 09:01:00

Foreign Stocks: Looking Beyond Index Valuations

2015-12-20 01:00:00

Why These Investors Overhauled Their Portfolios

2015-12-14 13:20:55

FEZ and EWJ Fall as Crude Oil Prices Plunge Further

2015-12-09 17:54:00

DuPont-Dow Megadeal Talk Stirs Materials ETFs

2015-12-09 08:06:31

Kite Pharma Leads IBB’s Mid-Caps on Its Zuma-1 Phase 1 Results

2015-12-08 18:56:00

Oil ETFs Dig A Hole But Could Syria Change That?

2015-12-08 13:06:33

Consumer Staples Didn’t Fall into Equity Market’s Downtrend

2015-12-08 13:03:47

SPY Ended Negative as Oil Sank to New Lows

2015-12-08 12:07:52

Alexion Tops IBB’s Large-Caps on Release of New Research Data

2015-12-07 18:13:00

Jet ETF Climbs, Dow In Red For 2015 As Oil Weighs

2015-12-07 17:34:05

Financial Sector Catches a Rate Hike Tailwind on December 4

2015-12-07 17:34:00

Gung-Ho US Employment Scene Catapults SPY on December 4

2015-12-07 15:45:31

How Are IBB’s American Depositary Receipts Performing?

2015-12-07 11:52:13

FEZ Rises by 1.2% on Strong Employment Data

2015-12-07 07:05:36

IHI’s Small Caps Outperformed the Market

2015-12-07 07:05:33

Abiomed Rose 1% on High Trading Volume

2015-12-05 07:40:00

These 3 ETFs Jumped in November

2015-12-04 18:23:00

Gold Mining ETFs Spike As Metal Shines

2015-12-04 15:07:25

Mallinckrodt Rose after Sale of Contrast Media & Delivery System

2015-12-04 14:06:29

Rate Hike Hints Boost November Fund Flows of $731 Million in XLF

2015-12-04 07:00:00

A Low-Cost Way to Bet on Banking

2015-11-25 11:12:07

3 Big Market Movers This Week

2015-11-05 19:47:28

U.S.-based stock funds attract $5.7 bln in latest week -Lipper

2015-09-13 21:40:00

Is The U.S. Economy Going To Crash This Year?

Comments

You have to sign in to write a comment.

No comments yet.